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Methyl‑CpG binding protein 2 (MeCP2) is an epigenetic regulator, which preferentially binds to methylated CpG dinucleotides in DNA. 
MeCP2 mutations have been linked to Rett syndrome, a neurodevelopmental disorder characterized by severe intellectual disability in 
females. Earlier studies indicated that loss of MeCP2 function in neuronal cells was the sole cause of Rett syndrome. Subsequent studies 
have linked MeCP2 expression in CNS glial cells to Rett syndrome pathogenesis. In this review, we have discussed the role of MeCP2 in 
glial subtypes, astrocytes, oligodendrocytes and microglia, and how loss of MeCP2 function in these cells has a profound influence on 
both glial and neuronal function. 
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INTRODUCTION 
Epigenetic regulation of genes plays an important role 
in the development and function of the central nervous 
system (CNS). Proper regulation of stage‑specific gene 
expression in the nervous system is modulated by epi‑
genetic mechanisms such as DNA methylation, histone 
modifications, nucleosome/chromatin remodeling, and 
non‑coding RNA‑mediated posttranslational regulation 
(Hsieh and Gage 2005, Wu and Sun 2006). Among these 
mechanisms, DNA methylation regulates the expression of 
genes by either inhibiting the binding of transcription fac‑
tors, or the recruitment of methyl binding domain (MBD) 
family proteins that includes MeCP2, MBD1, MBD2, MBD4, 
and Kaiso protein (Bird 2002, Guoping and Hutnick 2005). 
MeCP2 is a member of the MBD protein family that binds 
to 5‑methylcytosine (5mC) (Meehan et al. 1992). MeCP2 
requires an A/T run of four or more base pairs adjacent 
to the methyl‑CpG for efficient DNA binding (Klose et al. 
2005). Interestingly, disruption of the AT‑hook domain in 
the transcription repression domain (TRD) of MeCP2 leads 
to defects in chromatin organization, and thus changes 
the Rett syndrome phenotype (Baker et al. 2013). MeCP2 
also interacts with hydroxyl methyl‑CpG (5hmC), which is 
enriched within active genes (Mellén et al. 2012). In ad‑
dition to the classic dinucleotide methyl‑CG(mCG) MeCP2 
has been recently reported to bind to cytosine methylated 
trinucleotide (mCAC) (Lagger et al. 2017). 
MECP2 is an X‑linked gene, mutation of which results 
in the multiple phenotypes that fall under the umbrella 
of Rett syndrome. Rett syndrome is a neurodevelopmen‑
tal disorder which occurs mostly in females (Amir et al. 
1999) and has been reported to have an incidence of ap‑
proximately 1/10,000 live female births. Rett syndrome 
is characterized by normal post‑natal development up 
to 6 months, followed by a subsequent loss of acquired 
speech and motor skills. The most pronounced changes 
occur at 12‑18 months of age. Rett patients may also de‑
velop mental retardation, stereotyped hand movements, 
ataxia, seizures (after the age of 2) microcephaly, autism 
and respiratory dysfunctions (Hagberg et al. 1983, Nomu‑
ra 2005). There is currently no cure for Rett, and most 
girls live for many years, even decades, requiring contin‑
uous supervision and assistance. 
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Glial cells in the CNS consist of astrocytes, oligo‑
dendrocytes, and microglia. Astrocytes maintain and 
regulate the level of ions and neurotransmitters at 
the synapse, provide nutrients and structural support 
around synapses, and contribute to the integrity of the 
blood‑brain barrier (Wang and Bordey 2008). On the 
other hand, oligodendrocytes (OL) produce and main‑
tain the myelin sheath around the axons, allowing the 
rapid conduction of nerve impulses. OL also provides 
trophic support to axons. In addition to providing in‑
sulation and trophic support to neurons, myelinating 
glia are critical for the proper functioning of the ner‑
vous system, supporting the structural and electrical 
properties of axons by controlling their diameter, as 
well as the spacing and clustering of ion channels at 
nodes and paranodes (Baumann and Pham‑Dinh 2001). 
Lastly, microglia are the resident inflammatory cells 
of the brain and are involved in the regulation of syn‑
aptic function (Tremblay et al. 2011). Early studies 
suggested that MeCP2 is expressed only in neurons 
where its expression correlates with neuronal matu‑
ration. It was thought to be absent in glial cells (Jung 
et al. 2003, Kishi and Macklis 2004, Shahbazian et al. 
2002). In 2010, we showed the MeCP2 expression in 
OL (Vora et al. 2010). Subsequent studies demonstrate 
MeCP2 expression in all glial cells including astro‑
cytes, and microglia (Ballas et al. 2009, Maezawa and 
Jin 2010, Sharma et al. 2015, Tochiki et al. 2012, Vora 
et al. 2010). Rett syndrome has primarily been associ‑
ated with functional loss of MeCP2 solely in neuronal 
cells. However, increasing evidence has demonstrated 
that genetic rescue of MeCP2 in glial cells also signifi‑
cantly improves the disease phenotypes, which indi‑
cate that glial cells, like neurons, are integral to Rett 
syndrome pathogenesis (Cronk et al. 2015, Lioy et al. 
2011, Nguyen et al. 2013). This review elaborates and 
emphasizes the role of MeCP2 in CNS glial cells, how its 
loss in CNS glia affects cell functioning, and the possi‑
ble implications in Rett syndrome pathology. We first 
discuss the current knowledge of MeCP2 structure and 
function. Subsequently, we examine the contribution 
of MeCP2 in glial cell function, and the potential impli‑
cation in Rett syndrome pathology. 
Structure and Function of MeCP2
The MeCP2 protein comprises of structural do‑
mains: N‑terminal domain (NTD), MBD, the interven‑
ing domain (ID), TRD and the C‑terminal domain (CTD) 
(Fig. 1). Among these, the MBD domain of MeCP2 is 
essential for its binding to methyl CpG dinucleotides, 
which is linked with most of the disease causing muta‑
tions. TRD is required for its association with co‑repres‑
sor proteins for transcriptional repression. Pathogenic 
mutations in the ID and CTD domains suggest their 
Fig. 1. Structure and Splicing of MeCP2. MeCP2 upon alternative splicing form two different isoform (MeCP2-e1 and MeCP2-e2). MeCP2-e1 is 498 amino 
acids long and has 21 unique N-terminal residues (vertical green stripes). MeCP2-e2 is 486 amino acids long and has 9 unique residues (horizontal green 
stripes). The remaining protein sequence is common to both isoforms and can be divided in following domains: the NTD (N‑terminal domain), the MBD 
(methyl‑CpG binding domain), the ID (intervening domain), the TRD (transcription repression domain), the CTD (C‑terminal domain), the AT‑Hook domain, 
the NCOR‑‑SMRT interaction domain (NID).
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importance in MeCP2 dysfunction (Bedogni et al. 2014, 
Hansen et al. 2010, Lew is 1992, Yusufzai and Wolffe 
2000). In addition, there are NCoR/SMRT interaction 
domain (NID) and AT‑hook like domains that have been 
mapped in MeCP2. Mutation in the NID and AT‑hook 
domains disrupts interactions with partner proteins 
and results in Rett syndrome (Baker et al. 2013, Leonard 
et al. 2017, Lyst et al. 2013). 
MeCP2 has two isoforms (MeCP2_E1 and MeCP2_E2) 
produced by alternative splicing of mRNA (Fig. 1). 
In the brain, the MeCP2_E1 isoform is expressed at 
10 times to the level of MeCP2_E2 (Mnatzakanian et al. 
2004). The expression of MeCP2_E1 is markedly higher 
in primary neurons, as compared to primary astrocytes 
(Kaddoum et al. 2013, Zachariah et al. 2012). Dastidar 
and colleagues showed that the two isoforms are func‑
tionally different (Dastidar et al. 2012). They showed 
that elevated expression of MeCP2_E2 isoform promotes 
neuronal death by suppressing the expression of FoxG1. 
FoxG1 is a protein that promotes neuronal survival by 
inhibiting MeCP2_E2 activated cell death. Mutations in 
FoxG1are also found in Rett syndrome (Dastidar et al. 
2012). MeCP2_E2 is functionally redundant for devel‑
opment of the CNS, but is involved in embryo viabil‑
ity and placenta development. Further, mutations in 
the MeCP2_e2 gene confer a survival disadvantage for 
carriers of the maternal allele (Itoh et al. 2012). Al‑
though MeCP2_e2 is thought to not be involved in Rett 
syndrome development, it may result in a phenotype 
that is not currently classified under the Rett umbrella. 
Mutation of MeCP2_E1 results in classic Rett syndrome 
(Itoh et al. 2012). DNA methylation pattern at the regu‑
latory elements of MeCP2 may regulate the differential 
expression of its two isoforms in specific brain regions 
(Olson et al. 2014). 
MeCP2 has a highly disorganized structure that 
acquires local secondary structure upon binding to 
other macromolecules, thereby inviting multiple pro‑
tein‑protein interactions. Post‑translation modifica‑
tion of MeCP2 also regulates its activity and interac‑
tion with other proteins (Bedogni et al. 2014). Neu‑
ronal activity, specifically release of glutamate at the 
synapse, regulates MeCP2 action by dephosphorylation 
and phosphorylation at serine 80 (S80) and 421 (S421) 
respectively, which regulates transcription of target 
genes. Phosphorylation of MeCP2 at S421 leads to the 
transcriptional induction of Bdnf gene (Zhou et al. 
2006). Mutation of Mecp2 at S421A in mice results in de‑
fective synaptic development and abnormal behavior. 
Contrary to S421, S80 is dephosphorylated by neuronal 
activity, which weakens its binding to chromatin (Tao 
et al. 2009). Interestingly, chromatin immunoprecipi‑
tation (ChIP) sequencing shows that phosphorylation 
of S421does not regulate gene expression, it appears 
that MeCP2 functions as histone‑like factor, when 
phosphorylated at S241. In this way, it facilitates a ge‑
nome‑wide response of chromatin to neuronal activity 
(Cohen et al. 2011). Further to this, MeCP2 deletion re‑
sults in a genome‑wide increase in acetylated histone 3 
and histone 1. 
Recent studies have shown that MeCP2 phosphor‑
ylation at three sites (S86, S274, and T308) is induced 
differentially by neuronal activity, BDNF and other 
agents that increase the intracellular cAMP levels. 
Phosphorylation at T308 site inhibits its interaction 
with NCoR co‑repressor complex, and thus suppress‑
es the MeCP2 mediated transcriptional repression. 
These findings suggest that loss of MeCP2 and NCoR /
SMRT co‑repressor interaction leads to Rett syndrome 
(Ebert et al. 2013, Lyst et al. 2013). MeCP2 regulation 
of target gene expression is mediated through its in‑
teraction with other partner proteins, including co‑re‑
pressors mSIN3a (Nan et al. 1998), cSki (Kokura et al. 
2001), transcription factor Ying Yang 1 (YY1), which is 
involved in activation as well as repression (Forlani et 
al. 2010), YB1 (RNA interacting protein) (Young et al. 
2005), Swi/Snf family ATPase α‑thalassemia/mental re‑
tardation syndrome X linked (Atrx) (Nan et al. 2007), 
nuclear receptor co‑repressor (NcoR) and DNA methyl 
transferase 1 (Dnmt1) (Kokura et al. 2001). In addition, 
MeCP2 also binds to the corepressor of RE1 silenc‑
ing transcription factor (CoREST) (Ballas et al. 2005), 
the transcriptional activator cAMP response element 
binding protein (CREB) (Chahrour et al. 2008) and the 
tri‑thorax‑related protein Brahma (Harikrishnan et al. 
2005). Further, recent studies have shown that MeCP2 
binds to GC‑rich sequences in correlation with nucleo‑
some binding (Rube et al. 2016). It is believed that the 
genome wide binding, post‑translational modification 
and differential phosphorylation states contribute to 
the multifunctional properties of MeCP2. 
Although a ubiquitous protein in nature, MeCP2 
is most predominantly expressed in the brain, and is 
highly expressed in neuronal cells compared to oth‑
er cell types. Its expression level correlates with the 
maturation of neurons which suggests the notewor‑
thiness of MeCP2 in neuronal maturation and mainte‑
nance (Kishi and Macklis 2004, Shahbazian et al. 2002). 
MeCP2 density in neuronal nuclei was found to be as 
abundant as histone octamer. Neuronal loss of MeCP2 
results in changes in chromatin organization mediat‑
ed by the increase in histone acetylation and doubling 
of histone H1 (Skene et al. 2010). Further, it also regu‑
lates the nuclear size and RNA synthesis levels in neu‑
rons during their maturation (Yazdani et al. 2012). This 
implicates MeCP2 as a global regulator of chromatin 
states instead of gene specific regulator. In dorsal horn 
neurons, post inflammation, MeCP2 phosphorylation 
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leads to increased expression of target genes such as 
the serum‑ and glucocorticoid‑ regulated kinase (Sgk1): 
FK 506 binding protein 5 (Fkbp5), a glucocorticoid re‑
ceptor‑regulating co‑chaperone of hsp‑90, and the sul‑
fotransferase family 1A, phenol‑preferring, member 1 
(Sult1A1). SGK1 supports the induction of ankle joint 
inflammation. Moreover, MeCP2, DNMT and histone 
deacetylase (HDAC) levels are modulated within the 
superficial dorsal horn during the maintenance phase 
of persistent pain states, indicating a prominent role 
of MeCP2 in chromatin organization during the main‑
tenance phase of chronic pain (Géranton et al. 2007, 
Tochiki et al. 2012). 
MECP2 duplication, or over expression, leads to 
MECP2 duplication syndrome, which is specific in 
males but can also be found in females. This syndrome 
may initially resemble Rett syndrome, but the disor‑
der is more clinically severe, and presents differently 
from classic Rett syndrome (Ramocki et al. 2010). MBD 
and TRD are responsible for toxicity in MECP2 duplica‑
tion syndrome (Heckman et al. 2014). Furthermore, the 
over expression of MeCP2 impairs chick embryo neural 
tube formation by provoking premature differentia‑
tion of proliferating progenitors (Petazzi et al. 2014). 
The severity of neurological symptoms in Rett patients 
also depends on X‑chromosome inactivation (XCI) 
patterns (Braunschweig et al. 2004). Most of the Rett 
syndrome female patients are heterozygous for MECP2 
mutation due to random XCI. Deficiency of MeCP2 in 
the Mecp2 mosaic mouse model may not affect primary 
XCI in early development, but does affect the propor‑
tion of neurons expressing the wild‑type Mecp2 allele 
in both a region‑ and age‑dependent manner (Smrt et 
al. 2011). 
The classical function of MeCP2 is to silence the 
gene expression through the recruitment of corepres‑
sors comprising HDAC and mSIN3 (Nan et al. 1998). Bdnf 
is the archetypal target gene, whose expression is mod‑
ulated by MeCP2, and has been shown to be involved 
in neuronal survival, differentiation, and synaptic plas‑
ticity. Previous work has shown that MeCP2 represses 
the expression of BDNF, and is regulated by neuronal 
membrane depolarization. Neuronal membrane depo‑
larization phosphorylates MeCP2 causing its dissoci‑
ation from the Bdnf promoter (Chen et al. 2003, Mar‑
tinowich et al. 2003, Zhou et al. 2006). Further, it was 
demonstrated that BDNF protein levels are lower in the 
brain of Mecp2 knockout mice (Chang et al. 2006, Li et 
al. 2012) and increased in mice over expressing Mecp2 
(Chahrour et al. 2008). These observations imply an im‑
portant role for altered BDNF level in Rett syndrome 
disease progression. In contrast to earlier studies, BDNF 
protein levels were seen to be enhanced in both MeCP2 
knock out and MeCP2 over expressing cultured hippo‑
campal neurons (Larimore et al. 2009). These findings 
suggest that the control of BDNF expression by MeCP2 
can dynamically switch between repression and acti‑
vation. Epigenetic studies have established that MeCP2 
acts as a transcriptional repressor, but a recent report 
by Zoghbi and colleagues demonstrates that MeCP2 ac‑
tivates expression of target genes in the hypothalamus 
and cerebellum in mice over expressing MeCP2. MeCP2 
is associated with transcriptional activator CREB1 at 
the promoter region of an activated target but not at 
a repressed target (Ben‑Shachar et al. 2009, Chahrour 
et al. 2008). 
Astrocytes and MeCP2
The expression of several glial genes, including α 
B‑crystallin, glial fibrillary acidic protein (Gfap), glial 
excitatory amino acid transporter 1 (Eaat1) and S100A13 
were found to be increased in Rett syndrome brain 
(Colantuoni et al. 2001). Apart from neuronal MeCP2, 
several studies have shown the non‑cell autonomous 
influence of astrocytic MeCP2 on neuronal cells and its 
contribution to Rett syndrome pathogenesis. In fact, 
astrocytes from Rett syndrome mouse model fail to 
support normal neuronal growth and cause dendritic 
abnormalities, further supporting a significant role for 
MeCP2 in neuronal maturation. Moreover, conditioned 
media from Mecp2 null astrocytes results in neuronal 
damage, suggesting the aberrant secretion of toxic fac‑
tors by mutant astrocytes (Ballas et al. 2009). In a sim‑
ilar line of studies, MeCP2 deficiency in astrocytes has 
also been correlated with abnormal growth and alter‑
ations in BDNF expression levels. MeCP2 also regulates 
astrocyte immune response by altering the expres‑
sion of pro‑inflammatory cytokines (TNFα, IL‑1β, and 
IL‑6) and p38MAPK (Maezawa et al. 2009). The astrog‑
lial marker GFAP and S100β expression levels are sup‑
pressed in MeCP2 siRNA treated amygdala of female rat 
brain (Forbes‑Lorman et al. 2014), suggesting negative 
regulation by MeCP2. 
MeCP2 deficient astrocytes cause abnormal den‑
dritic arborization of wild neuron in co‑culture, which 
is a prominent neurological feature of Rett syndrome 
brain. Mutant astrocytes differentiated from isogenic in‑
duced pluripotent stem cell (iPSC) lines from human Rett 
syndrome patients also adversely affect the morphology 
and function of wild type neurons from mouse and hu‑
man and such non‑cell autonomous effects are partial‑
ly mediated by secreted factors (Williams et al. 2014). 
These negative effects on neurons could be mediated by 
either the presence or absence of growth promoting or 
inhibiting factors respectively, in the conditioned media 
of mutant Rett syndrome astrocytes. Further studies are 
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needed to fully identify these factors in order to develop 
an effective gene‑therapy for Rett syndrome. 
MeCP2 expression in GFP‑labeled wild type astro‑
cytes was reduced in a time‑dependent manner when 
co‑cultured with Mecp2‑/+ astrocytes. This non cell au‑
tonomous effect is mediated via gap junctions, specif‑
ically Cx‑43‑containing gap junctions. These observa‑
tions suggest that MeCP2 deficiency spreads through 
Mecp2‑/+ tissue via the non‑cell autonomous transfer of 
MeCP2 suppressor via gap junctions. These negative 
regulators may include Ca2+, inositol trisphosphate, 
glutamate, or small regulatory miRNAs, such as miR132 
that post transcriptionally down regulates MeCP2 
(Klein et al. 2007, Maezawa et al. 2009). 
Preferential re‑expression of MeCP2 in the astro‑
cytes of MeCP2 deficient mice restores the Rett syn‑
drome phenotype. Specifically, locomotion, anxiety 
levels and respiratory abnormalities return to a normal 
pattern, and the mice live longer. This indicates that 
glia are an integral component in the neuropatholo‑
gy of Rett syndrome (Lioy et al. 2011). Abnormal glu‑
tamate metabolism has been found in Rett syndrome 
brain. MeCP2 impaired the glutamate clearance rate of 
Mecp2 null astrocytes by regulating glutamate trans‑
porters and glutamine synthetase, which may further 
influence the progression of Rett syndrome (Okabe et 
al. 2012). 
Astrocytes from MeCP2 deficient mice show reduced 
expression of stathmin‑like 2 (STMN2) protein that re‑
sults in altered microtubule assembly and dynamics. 
STMN2 promotes astrocytic microtubule disassembly 
and it’s down regulation in MeCP2 deficient astrocytes 
increase microtubule growth. Since astrocytes are also 
involved in dendritic outgrowth and synaptogenesis, 
it was thought that STMN2 down regulation in MeCP2 
deficient astrocytes may explain the dendritic abnor‑
malities observed in Rett syndrome brain (Nectoux and 
Floria 2012, Slezak and Pfrieger 2003). However, re‑
cent studies have shown that microtubules dynamics 
and vesicular transport is altered in astrocytes derived 
from Mecp2308/y mice, and human astrocytes derived 
from iPSC from a Rett syndrome patient with a MECP2p. 
Arg294 mutation. Impaired microtubule dependent dy‑
namics and vesicular transport in MeCP2 deficient as‑
trocytes was found to be restored upon treatment of 
microtubule stabilizing agent EpothiloneD (EpoD). 
Thus, microtubules may be potential therapeutic target 
for Rett syndrome (Delépine et al. 2016). MeCP2 defi‑
ciency is also found to be associated with reduced sen‑
sitivity of medullary astrocytes to changes in PCO2/[H+] 
(Turovskyet al. 2015). MeCP2 deficiency alone, in astro‑
cytes, significantly depresses the hypercapnic ventila‑
tory response in mice. These results suggest a role for 
astrocytes in the regulation of respiratory response to 
CO2 and further suggest a role for astrocytic MeCP2 in 
respiratory abnormalities observed in Rett syndrome 
(Garg et al. 2015). 
In a study, NTera‑2, a human embryonal carcino‑
ma cell line, was induced to differentiate into astro‑
cytes (Cheng et al. 2011). It was observed that MeCP2 
in association with Sin3A inhibits the differentiation of 
NTera‑2 into astrocyte‑like lineage by suppressing GFAP 
expression. Upon differentiation, the promoter under‑
goes a conformational change triggered by STAT3 bind‑
ing that causes the release of Sin3A/MeCP2 complex and 
Gfap gene activation. Moreover, MeCP2 deficiency in Rett 
syndrome‑human iPSC derived neural stem cells result‑
ed in an increase in the number of differentiated astro‑
cytes and dysregulation of GFAP expression (Andoh‑No‑
da et al. 2015). Finally, all the above studies indicate 
a role for MeCP2 in cellular differentiation and lineage 
specific gene expression. 
A combined approach of gene expression microar‑
ray and MeCP2 ChIP‑seq in astrocytes found a set of 
potential MeCP2 target genes whose products are in‑
volved in normal astrocytic signaling, cell division and 
neuronal support functions, the loss of which may con‑
tribute to the Rett syndrome phenotype (Yasui et al. 
2013). Validation of selected target gene transcripts 
by qRT PCR revealed that MeCP2 deficiency in astro‑
cytes consistently affects the expression of Apoc2, Cdon, 
Csrp and Nrep apolipoprotein C‑II (Apoc2). Cell adhe‑
sion molecule‑related/downregulated by oncogenesis 
(Cdon) and cysteine and glycine‑rich protein 1 (Csrp) 
expression levels are elevated in MeCP2 deficient mice, 
while the neuronal regeneration‑related protein (Nrep) 
expression levels are reduced (Yasui et al. 2013). De‑
fects in Apoc2 and Cdon expression in astrocytes may 
be associated with cardiac defects and brain structure 
abnormalities observed in Rett syndrome. Csrp1, which 
is upregulated in astrocytes in absence of MeCP2, ap‑
pears to have a role in neuronal regeneration. Nrep is 
an important factor involved in glial mobility and neo‑
plasia. Gene expression profiles of wild‑type and mu‑
tant astrocytes from Mecp2308/y mice demonstrate two 
interesting genes encoding secreted proteins, chro‑
mogranin B (Chgb) and lipocalin 2 (Lcn2). Both of which 
are dysregulated in MeCP2 deficient astrocytes and ex‑
ert negative non‑cell autonomous effects on neuronal 
properties (Delépine et al. 2015). LCN2 secreted by re‑
active astrocytes is involved in binding and transport 
of lipids and other hydrophobic molecules. Interesting‑
ly, LCN2 plays an important role in the regulation of 
neuronal excitability and spine morphology (Ferreira 
et al. 2013). Chgb, a component of exocytosis vesicles 
was found in the secretory granule cargoes involved 
in BDNF secretion (Sadakata et al. 2004). Another im‑
portant molecule nuclear receptor subfamily 2, group 
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F, member 2 (Nr2f2) was found to be dysregulated in 
MeCP2 deficient astrocytes and is involved in down 
and up‑regulation of several target genes in astrocytes, 
such as chemokine (C–C motif) ligand 2 (Ccl2): Lcn2 and 
Chgb. This suggests knowledge of the involvement of 
Nr2f2 in MeCP2 deficient astrocytes could lead to bet‑
ter understanding of Rett syndrome pathophysiology 
(Delépine et al. 2015). In addition, the astrocytic gluta‑
mate transporter GLAST, the GPCRs mGluR3 and S1P1, 
along with protein‑ binding partners Moesin, Merlin, 
and PTEN were disrupted in transcriptomic or pro‑
teomic data from MeCP2 deficient mice. Further, there 
were reduced expression of markers associated with re‑
active astrocytes (Gfap, Gap43, Vim, HSPB1, and ANXA3) 
suggesting decreased astrocytic reactivation in Rett 
syndrome (Pacheco et al. 2017). In a different study, 
it was found that ischemia induced the expression of 
Phospho‑S292 MeCP2 in reactive astrocytes accompa‑
nied by enhanced expression of vascular endothelial 
growth factor (VEGF) in the striatum. In addition, over 
expression of VEGF in ischemia‑injured striatum in‑
creases the accumulation of pS292 MeCP2 in reactive 
astrocytes (Liu et al. 2015), suggesting a role for MeCP2 
in the modulation of reactive astrocyte function. 
Oligodendrocytes and MeCP2
Brain magnetic resonance imaging in Mecp2‑/y mice 
detected a significant reduction in the thickness of the 
corpus callosum (Saywell et al. 2006). Diffusion tensor 
imaging (DTI) studies in Rett syndrome patients also 
found a significant reduction in fractional anisotropy 
(FA) in the corpus callosum (Mahmood et al. 2010). MRI 
studies have also shown alterations in cerebellar white 
matter, and corpus callosum of all available MeCP2 mu‑
tant mice currently available (Allemang‑Grand et al. 
2017). These results correlate with white matter im‑
pairment seen in human Rett syndrome patients. My‑
elin‑associated oligodendrocytic basic protein (MOBP) 
is one of the myelin proteins that may be involved in 
the compaction or stabilization of myelin but the exact 
function of MOBP is still unclear (Montague et al. 2006). 
Mobp was found to be up‑regulated in Mecp2 null mice, 
and is directly regulated by MeCP2 binding through its 
promoter (Urdinguio et al. 2008). Myelin genes such 
as myelin basic protein (Mbp) and myelin associated 
glycoprotein (Mag) have been found to be increased in 
the corpus callosum of Mecp2308/y mouse brain (Vora et 
al. 2010). Major CNS myelin proteins, including MBP, 
proteolipid protein (PLP) and MAG play an important 
role in myelin sheath formation and integrity. PLP and 
MBP are distributed throughout the myelin sheath and 
are essential for compaction of myelin. MAG is locat‑
ed in the periaxonal regions and may serve to facili‑
tate cell–cell interactions between oligodendrocytes 
and axonal membranes during myelination (Baumann 
and Pham‑Dinh 2001, Fulton et al. 2010). The expres‑
sion of CNPase, another myelin specific protein, is 
also reduced in the white matter and hippocampus of 
a Rett syndrome mouse model (Wu et al. 2012). F2‑Di‑
homo‑isoprostanes (F2‑Dihomo‑IsoP), peroxidation 
products from adrenic acid, a known component of my‑
elin were found to be increased by about two orders of 
magnitude in patients in stage I of Rett syndrome and 
decreased in later stages of disease progression. This 
increased level of F2‑Dihomo‑isoprostanes in patients 
suggests early white matter damage in Rett syndrome 
brain. Some neurological signs in Rett syndrome pa‑
tients overlap with X‑linked adrenoleukodystrophy 
and supports the theory of white matter damage in 
Rett syndrome (Durand et al. 2013). 
Studies carried out in our laboratory have shown 
that MeCP2 knock‑down in cultured rat oligodendro‑
cytes results in the increased expression of several my‑
elin genes, including Mbp, Plp, Mog, Mobp, Bdnf and the 
transcriptional regulator Yy1. These results indicate 
that MeCP2 acts as negative regulator of myelin gene 
expression in oligodendrocytes (Sharma et al. 2015). 
Recently, the Nurit Ballas group has shown a significant 
contribution of oligodendrocytes in Rett syndrome pa‑
thology (Nguyen et al. 2013). Mice lacking oligoden‑
drocyte specific MeCP2 developed a severe hind‑limb 
clasping phenotype. Restoration of oligodendrocyte 
MeCP2 resulted in significant improvement of some 
Rett syndrome phenotypes specifically the hind‑limb 
clasping phenotype. Moreover, the loss of MeCP2 in 
oligodendrocyte lineage cells does not affect the ex‑
pression pattern of proteins (MBP and PLP) involved 
in myelination. However, the myelin genes Mbp and Plp 
were found to be impaired in Mecp2Stop/y mouse brain. 
MBP expression was reduced while the PLP protein lev‑
el was increased in Mecp2Stop/y mice brain. MBP levels 
were only partially restored upon expression of MeCP2 
in oligodendrocytes while levels of PLP remained un‑
changed (Nguyen et al. 2013). These data imply MeCP2 
expression in oligodendrocytes has little effect on the 
expression of myelin‑related proteins. Further studies 
are required to clarify these findings. However, one ex‑
planation is the non‑cell autonomous effect of another 
cell, either neuronal or glial, on the expression of my‑
elin proteins. 
RNA sequencing and proteomics data from MeCP2 
deficient mice revealed disruption of the pathways re‑
lated to morphology, migration and myelination/de‑
myelination of oligodendrocytes (Pacheco et al. 2017). 
In addition, it was identified that increased expres‑
sion of MeCP2E1 in an EAE model of multiple sclero‑
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sis hampers the myelin repair process by repressing 
the BDNF levels (Khorshid et al. 2017). The regulation 
and function of MeCP2 phosphorylation in neurons 
and astrocytes is well known. Currently, our group 
has demonstrated differential regulation of MeCP2 
phosphorylation at S80 in N19 (mouse oligodendrog‑
lial cell line) in response to the extracellular matrix 
component (ECM) laminin (Parikh et al. 2017). Lami‑
nin increases the level of pS80 MeCP2 in immature oli‑
godendrocytes, and reduces level in mature oligoden‑
drocytes (Parikh et al. 2017). 
Microglia and MeCP2
Microglia primarily function as immune cells in 
the brain after injury or disease. However, microglia 
are also involved in normal synaptic function. Studies 
have also shown that all cell types in the brain, both 
neuronal and non‑neuronal, communicate via re‑
lease of soluble factors in the mature and aging brain 
(Tremblay et al. 2011). For example, conditioned me‑
dia from Mecp2 null microglia contains high levels of 
glutamate, which is neurotoxic. Wild type neurons 
treated with Mecp2 null microglia conditioned media 
show abnormal dendritic morphology, signs of micro‑
tubule disruption and damage of postsynaptic gluta‑
matergic components (Maezawa and Jin 2010). Previ‑
ous studies on astrocytes demonstrated that MeCP2 
deficient astrocytes detrimentally influence neuronal 
dendrite formation (Ballas et al. 2009, Maezawa et al. 
2009). The Ballas group suggest that Mecp2 null astro‑
cytes release a soluble neurotoxic factor with slow ac‑
tivity that requires incubation of at least 3 days in cul‑
ture, but the factor has not been identified. Further, 
Maezawa and Jin (2010) found that wild type neurons, 
treated with conditioned media derived from prima‑
ry mixed glial culture from Mecp2 null mice, show 
dendritic damage while conditioned media from the 
highly pure culture of Mecp2 null astrocytes show no 
dendritic abnormalities. They suggest this is due to 
the microglia present in mixed glial culture releasing 
the neurotoxic factor. Wild type neurons treated with 
conditioned media from Mecp2 null microglia, show 
robust dendritic abnormalities. Due to an abnormally 
high level of glutamate released byMecp2 null microg‑
lia, which causes excitotoxicity that may contribute 
to dendritic and synaptic abnormalities in Rett syn‑
drome (Maezawa and Jin 2010). Further, it was identi‑
fied that increased levels of glutaminase and connexin 
32 in Mecp2 null microglia are responsible for excess 
glutamate production and release, respectively. This 
explains that microglia, and not astrocytes, are the 
major source of soluble neurotoxic factors (Maeza‑
wa and Jin 2010). Further in the same line, a recent 
report showed that MeCP2 deficiency leads to mito‑
chondrial dysfunction and neurotoxicity in microglia, 
by regulating glutamine homeostasis. MeCP2 acts as 
the repressor of major glutamine transporter sodi‑
um‑coupled neutral amino acid transporter 1 (SNAT1) 
in microglia. MeCP2 down regulation or SNAT1 over 
expression in microglia resulted in mitochondrial 
dysfunction and neurotoxicity due to overproduction 
of glutamate (Jin et al. 2015). 
It was observed that restoration of MeCP2 in mi‑
croglia attenuates the symptoms of Rett syndrome in 
the mouse model (Derecki et al. 2012). Thus, via multi‑
ple approaches, wild type Mecp2‑expressing microglia 
within the context of Mecp2 null male mouse altered 
numerous facets of disease pathology. For example, 
lifespan was increased, breathing patterns were nor‑
malized, apneas were reduced, body weight was in‑
creased to near wild type, and locomotor activity was 
improved. Mecp2+/− females also exhibited significant 
improvements as a result of wild type microglial en‑
graftment (Derecki et al. 2012). In addition, it has been 
observed that in MeCP2 deficiency condition, microg‑
lia are activated, but are lost with disease progression. 
Peripheral macrophage and monocytes population 
were also found to be depleted in Mecp2 null mice. 
Postnatal re‑expression of Mecp2 using Cx3cr1creERex‑
tends the lifespan of Mecp2 null mice. MeCP2 also reg‑
ulate glucocorticoid and hypoxia‑induced transcripts 
in MeCP2 deficient microglia and macrophages. Fur‑
ther, MeCP2 modulates the transcription of inflamma‑
tory genes in response to TNF stimulation of microg‑
lia (Cronk et al. 2015). However, another study com‑
pletely contradicts the findings of Derecki et al. 2012 
that transplantation of wild type microglia reverses 
the Rett syndrome pathology (Wang et al. 2015). This 
suggests a direct role for microglia in Rett syndrome 
pathogenesis is controversial. In addition, it has been 
demonstrated that microglia may contribute to Rett 
syndrome pathogenesis by excessively engulfing and 
eliminating the presynaptic inputs at the end stage 
of the disease, leading to synapse loss. While the spe‑
cific loss or gain of Mecp2 expression in microglia has 
a modest effect on abovementioned phenotype. This 
indicates that the effect mediated by microglia is sec‑
ondary and independent of microglia specific loss of 
Mecp2 expression (Schafer et al. 2016). More recently, 
it has been demonstrated that immune dysregulation 
and oxidative stress observed in Mecp2 null microglia 
in response to LPS could be attenuated by dendrimer 
based delivery of N‑Acetyl cysteine (NAC). This implies 
a potential for glial cell directed therapy using den‑
drimer conjugated NAC for Rett syndrome (Nance et al. 
2017). Intriguingly, ablation of CX3CR1, a chemokine 
MeCP2 regulates CNS glial cell functions 37Acta Neurobiol Exp 2018, 78: 30–40
receptor in microglia involved in neuron‑microglia in‑
teraction, improves the Rett syndrome like phenotype, 
including negative effects on neurons in Mecp2 knock 
out mouse. Further suggesting a therapeutic potential 
for CX3CR1 antagonists (Horiuchi et al. 2016). In an‑
other study transcriptomic data of microglia from Rett 
syndrome mouse models confirmed that MeCP2 defi‑
ciency differentially regulates the activation of cellu‑
lar stress genes that contribute to neurological symp‑
toms (Zhao et al. 2017). 
CONCLUSIONS
In summary, we have discussed the importance of 
glial cellMeCP2 in Rett syndrome pathophysiology 
and its role in the regulation of neuronal functions 
(Table I). Glial cells contribute significantly to the 
pathology of Rett syndrome and could be a potential 
future therapeutic target. Most of the studies to date 
have focused only on neuronal MeCP2 function relat‑
ed to Rett syndrome. Since MeCP2 is a genome wide 
modulator, future studies must be focused to unravel 
the role of MeCP2 in the regulation of glial cell func‑
tions like myelination, axo‑glial interaction, immune 
modulation, synaptic regulation and related diseases. 
Other neurological disorders have been shown to have 
MeCP2 involvement of include MeCP2 duplication syn‑
drome, X‑linked mental retardation, and autism, An‑
gelman Syndrome, Fetal Alcohol Spectrum Disorder, 
Schizophrenia and Huntington’s disease (Ezeonwuka 
and Rastegar 2014). Thus, there is an urgent need to 
explore the role of glial MeCP2 in neurological diseases 
at the cellular and molecular level. 
Table I. Summary of glial cells phenotype affected by MeCP2.
Cell type Phenotype MECP2 abnormalities References
Astrocytes
Failed to support neuronal growth and causes dendritic 
abnormalities
Mecp2tm1.1Bird
Ballas et al. 2009
Up‑regulation of BDNF expression, reduced pro‑
inflammatory cytokines (TNF-α, IL-1β and IL-6) released Maezawa et al. 2009
Increased expression of GFAP and S100β, Decreased 
glutamate clearance, Up‑regulation of glutamine synthatase Okabe et al. 2012
Reduced CO2 sensitivity Turovsky et al. 2015
Elevated expression of Apoc2, Cdon, and Csrp, reduced 
expression of Nrep Yasui et al. 2013
Up‑regulation of NR2F2 expression
Mecp2308/y
Delepine et al. 2015
Down‑regulation of STMN2 expression, increased 
microtubule growth, impaired microtubule dynamic, Altered 
microtubule dependent vesicle transport
Nectoux and Florian 2012; 
Delépine et al. 2016
Increased GFAP, S100β and BDNF expression, failed to 
support neuronal growth in in vitro Mecp2 siRNA
Forbes‑Lorman et al. 2014; 
Maezawa et al. 2009
Oligodendrocytes
Up‑regulation of Mbp, Plp, Mog, Mobp, Bdnf and Yy1 Mecp2 siRNA Sharma et al. 2015
Up‑regulation of Mobp expression Mecp2tm1.1Bird Urdinguio et al. 2008
Severe hand claspsing Phenotype Mecp2loxJ/y/NG2Cre
Nguyen et al. 2013
Down‑regulation of MBP and Up‑regultion of PLP Mecp2Stop/y
Reduced CNPase expression
Mecp2308/y
Wu et al. 2012
Increased expression of Mbp and Mag in corpus callosum 
and Plp in forebrain Vora et al. 2010
Microglia
Excess glutamate release, Increased glutaminase and Cx32 
expression, damage dendrites and synapse
Mecp2tm1.1Bird
Maezawa and Jin 2010
Up‑regulation of SNAT1, Increased ROS and glutamate, Less 
ATP production, Jin et al. 2015
Activated and depletion with disease progression, Incresead 
expression of glucocorticoid and hypoxia‑induced 
transcripts
Cronk et al. 2015
Differential expression of activation and cellular  
stress genes Zhao et al. 2017
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